New CFO Assumes Role at Intersect ENT

Intersect ENT Inc. has appointed Richard A. (Randy) Meier as executive vice president and chief financial officer (CFO).
 
Meier previously served as CFO and senior executive of Owens & Minor Inc., a global healthcare services company, including as president-International and executive vice president and CFO of Owens & Minor from 2013 to 2018, and as executive vice president and CFO from 2013 to 2015. Prior to joining Owens and Minor, Meier served as executive vice president and CFO at Teleflex Inc., a global medical device company, from 2010 to 2012. He served as president and chief operating officer of Advanced Medical Optics Inc., from 2007 to 2009, when the company was acquired as a wholly owned subsidiary of Abbott Laboratories. Meier joined Advanced Medical Optics, a global ophthalmic medical device company, as corporate vice president and CFO in 2002 and continuously served as CFO while simultaneously performing in a variety of finance and operations roles between 2002 and 2007. Meier also worked for ICN Pharmaceuticals Inc., now Bausch Health, a global pharmaceutical company, from 1998 to 2002, where he served as executive vice president and CFO, and as treasurer.
 
“Randy brings an impressive range of finance and operations expertise as well as device and pharmaceutical experience to this important Intersect ENT role,” said Thomas A. West, president and CEO of Intersect ENT. “Randy’s deep functional acumen and broad healthcare industry expertise will be a valuable addition to the executive team as the company aims to accelerate growth. I look forward to having him as a member of the Intersect ENT executive team and as a partner going forward.”
 
Meier serves on the board of BioMarin Pharmaceuticals Inc., where he is lead independent director. Meier is a graduate of Princeton University with a major in economics.

As previously announced, Jeryl (Jeri) Hilleman, Intersect ENT’s prior CFO, stepped down from the position as part of a planned transition allowing her to focus on board responsibilities outside of Intersect ENT. 
 
“I want to take this opportunity to thank Jeri for her many meaningful contributions to Intersect ENT since joining the company in 2014. We wish her the very best in the next phase of her career,” said West.
 
Intersect ENT is dedicated to transforming ear, nose and throat care by providing clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.